You are about to leave the CoverOne website and are being redirected to a non-CoverOne website. Neither EMD Serono nor Pfizer review or control the content of the following website. This redirection does not constitute an endorsement by EMD Serono or Pfizer of the following organization or any information provided by the organization.

REIMBURSEMENT SUPPORT SERVICES

CoverOne® will help you and your patients understand the specific coverage and reimbursement guidelines for BAVENCIO® (avelumab) 20mg/mL.

Reimbursement support services include:

  • Insurance Benefit Verification
  • Prior Authorization Assistance
  • Information on the relevant billing codes for BAVENCIO® - HCPCS, CPT, ICD-10-CM, NDC
  • Denied/Underpaid Claims Assistance
  • Payer Research (non -patient specific) - Medicare, Private Payers, State Medicaid

Please enroll through the CoverOne Enrollment Portal, or fax a completed CoverOne Enrollment Form to 1-800-214-7295 to request services.

When BAVENCIO is used in combination with axitinib, questions related to reimbursement and access for axitinib may be referred to Pfizer Oncology TogetherTM.
Pfizer Oncology TogetherTM provides personalized support and financial assistance resources to help patients access their prescribed axitinib. To learn more, call 1-877-744-5675 (Monday–Friday 8 AM–8 PM ET) or visit Pfizer Oncology Together.

EMD Serono, Inc and Pfizer Inc do not guarantee coverage and/or reimbursement for BAVENCIO. Coverage, coding, and reimbursement policies vary significantly by payer, patient, and setting of care. Actual coverage and reimbursement decisions are made by individual payers following the receipt of claims. Patients and healthcare professionals should always verify coverage, coding, and reimbursement guidelines on a payer and patient -specific basis

TERMS OF USE     PRIVACY POLICY     CONTACT US     SITE MAP     COOKIES SETTINGS

US-AVE-00860     January 2022
©2021 Merck KGaA, Darmstadt, Germany or its affiliates. All rights reserved. EMD Serono is the Healthcare business of Merck KGaA, Darmstadt, Germany, in the U.S. and Canada. BAVENCIO is a registered trademark of Merck KGaA, Darmstadt, Germany or its affiliates.

You are encouraged to report negative side effects of prescription drugs to the FDA. Visit http://www.fda.gov/medwatch, or call 1-800-FDA-1088. The health information contained herein is provided for educational purposes only and is not intended to replace discussions with a healthcare provider. All decisions regarding patient care must be made with a healthcare provider, considering the unique characteristics of the patient. The product information provided in this site is intended only for residents of the United States. The products discussed herein may have different product labeling in different countries.